Ozempic and type 1 diabetes: what adjunct semaglutide studies can answer

Ozempic is not FDA-approved to treat type 1 diabetes. Randomized studies in selected adults with type 1 diabetes tested semaglutide added to automated insulin delivery. Insulin remained part of the trial care. Those results raise a specialist question about adjunct treatment in a specific population and do not establish that Ozempic replaces insulin or is indicated for type 1 diabetes.¹²³

Why the trial and the label say different things

The Ozempic injection label lists glycemic control and certain cardiovascular and kidney risk reductions in defined adult populations with type 2 diabetes. That indication record is separate from studies that explore semaglutide in people with a different diagnosis. It is also separate from an obesity indication for another named product. A clinic should identify which product it means and which condition it proposes to address.¹

ADJUST-T1D enrolled 72 adults with type 1 diabetes and obesity who used automated insulin delivery. It compared semaglutide with placebo over 26 weeks. The primary outcome combined glucose time in range, a limit on time below range and weight reduction. Thirty-six percent of the semaglutide group and none of the placebo group reached the combination. That result describes a predefined composite in this study. It is not a measure of remission, an insulin-free outcome or a universal result for people with type 1 diabetes.²

Consider glucose, weight and adverse events separately

A second randomized crossover trial found an improvement in glucose time in range in the semaglutide period. It also reported episodes of ketosis without high glucose during semaglutide exposure. A favorable average glucose outcome cannot erase a safety observation. Neither small trial establishes uncommon-event frequency across people using different insulin systems or care arrangements.²³

Why an automated system matters to the study result

The trials did not observe an injection acting alone. Participants used automated insulin delivery, and the studies measured outcomes within that care setup. If a person uses a different delivery approach, that is a difference in study context that a diabetes clinician needs to consider. Likewise, continuous glucose readings answer questions about glucose patterns, while weight and adverse events have separate records. A study can report a better average glucose measure and still leave a question about what to do with a safety signal in a different setting. Neither average supplies an individual treatment plan.²³

Identify who owns the diabetes decision

When comparing medical weight management services, ask whether the clinic coordinates directly with the clinician who manages type 1 diabetes and the insulin delivery system. Ask how the proposed product and goal will be documented, and who is responsible for evaluating diabetes-related concerns if the plan changes. A weight-care visit can help define a separate goal without taking the place of diabetes specialist review.

For the broader medication reconciliation question, see GLP-1 medicines and insulin. It addresses low-glucose risk in a different evidence context. The type 1 trials add a focused research answer about a defined study population and an adjunct intervention.